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Therapies for most malignancies are generally ineffective once metastasis occurs.
While tumour cells migrate through tissues using diverse strategies, the signalling
networks controlling such behaviours in human tumours are poorly understood.
Here we deﬁne a role for the Diaphanous-related formin-3 (DIAPH3) as a non-
canonical regulator of metastasis that restrains conversion to amoeboid cell
behaviour in multiple cancer types. The DIAPH3 locus is close to RB1,w i t h i na
narrow consensus region of deletion on chromosome 13q in prostate, breast and
hepatocellular carcinomas. DIAPH3 silencing in human carcinoma cells destabi-
lized microtubules and induced defective endocytic trafﬁcking, endosomal
accumulation of EGFR, and hyperactivation of EGFR/MEK/ERK signalling. Silencing
also evoked amoeboid properties, increased invasion and promoted metastasis in
mice. In human tumours, DIAPH3 down-regulation was associated with aggressive
or metastatic disease. DIAPH3-silenced cells were sensitive to MEK inhibition, but
showed reducedsensitivitytoEGFRinhibition.Theseﬁndings haveimplicationsfor
understanding mechanisms of metastasis, and suggest that identifying patients
with chromosomal deletions at DIAPH3 may have prognostic value.
INTRODUCTION
Improving clinical options for metastatic disease requires an
understanding of the molecular basis for the complex
behaviours of metastatic cells. To date, however, few genetic
lesions in human tumours that promote selection of metastatic
variants have been identiﬁed.
Tumour cell migration can lead to metastatic dissemination.
The ability of carcinoma cells to transition from an adherent,
epithelial phenotype to a migratory, mesenchymal phenotype
(the epithelial-to-mesenchymal transition, EMT) is well estab-
lished, as are many signalling networks responsible for this
transformation (Kalluri & Weinberg, 2009). However, it has
recently been recognized that cancer cells can further transition
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amoeboid transition, MAT), characterized by a rounded
morphology, extensive actomyosin contractility, rapid exten-
sion and retraction of membrane protrusions (blebs), and
reduceddependenceonproteolysisformigration (Friedl&Wolf,
2010). Amoeboid cells are behaviourally plastic, move rapidly
through extracellular matrices by deforming their shape, and
expresssurfaceproteinsmoresymmetricallythanmesenchymal
cells, thus facilitating opportunistic responses to changes in
the microenvironment (Schmidt & Friedl, 2010). While such
characteristics enable cells to readily migrate through extra-
cellular matrix (ECM), the clinical impact of the amoeboid
phenotype is unknown. Additionally, EMT (Kalluri & Weinberg,
2009) and MAT (Wolf et al, 2003) are reversible processes, and
the ability of tumour cells to switch between these varied states
presents challenges in deﬁning critical signalling nodes where
metastasis might be inhibited. While the amoeboid phenotype is
potentially relevant to aggressive cancer (Sanz-Moreno &
Marshall, 2010), it has not been well studied in human tumours.
Chromosome13isfrequentlyalteredincancer, andtheq-arm
suffers predominantly from deletions (Beroukhim et al, 2010).
The RB1 locus at 13q14.2 is thought to be the dominant tumour
suppressor affected by copy number alterations. However,
reports speculate that another tumour suppressor resides in
this region, whose loss is associated with breast (Kainu et al,
2000) and invasive prostate (Dong et al, 2000) cancers,
and whose restoration can inhibit metastatic dissemination
(Hosoki et al, 2002).
Proximal to RB1,a t1 3 q 2 1 . 2 ,i st h eDIAPH3 locus encoding the
protein Diaphanous-related formin-3 [DIAPH3, (Peng et al,
2003)]. This protein belongs to a family of formin orthologs
(Chalkia et al, 2008) that nucleate, elongate and bundle linear
actin ﬁlaments and regulate microtubule dynamics (Bartolini &
Gundersen, 2010; Gaillard et al, 2011; Goode & Eck, 2007).
Formins are required for such fundamental processes as
endocytic trafﬁcking, mitosis, cell polarity and migration (Goode
& Eck, 2007). Despite the deregulation of these events in
pathological states such as cancer, the role of DIAPH3 in disease
is unexplored. We recently reported that genomic loss at DIAPH3
was linked to metastatic prostate cancer (Di Vizio et al, 2009).
However,giventhepropensityforchromosomallossalong13qin
multiple cancers (Beroukhim et al, 2010), whether DIAPH3
deletions are driver or passenger lesions remained unresolved.
We now demonstrate that genomic loss at DIAPH3 is
associated with multiple tumour types, and that DIAPH3 resides
at an important signalling node that controls the amoeboid
phenotype. We show that DIAPH3 silencing disrupts micro-
tubules,impairsendocytosisandpreventsEGFRdownregulation,
thereby enhancing EGFR activity and that of its downstream
effectors MEK and ERK. DIAPH3 deﬁciency also promotes
motility, invasion and experimental metastasis and signiﬁcantly
correlates with aggressive disease in human tumours.
RESULTS
Loss of DIAPH3 with tumour progression
To test whether genomic loss at DIAPH3 is a driver or passenger
effect consequent to the general instability of chromosome 13q,
we employed the genomic identiﬁcation of signiﬁcant targets in
cancer (GISTIC) platform (Beroukhim et al, 2010). GISTIC
identiﬁed regions of somatic copy number alterations (SCNA) in
a pooled analysis of 26 different cancer types, most of which are
not associated with previously validated tumour suppressor
genes. We hypothesized that signiﬁcant (q-value  0.25) focal
SCNA harbouring a tumour suppressor would emerge as a
consensus area across these cancers. Among the deletion peaks
on chromosome 13, one containing three genes, protocadherin
17 (PCDH17), tudor domain-containing protein 3 (TDRD3) and
DIAPH3, was located in a region common to three carcinomas
(prostate, breast and hepatocellular, Fig 1A). DIAPH3, near the
centre of this consensus region, was deleted in 32% of prostate,
46% of breast and 31% of hepatocellular carcinomas (Support-
ing Information Fig S1A). Together with the associated q-value
range of 0.052 q 0.132, these data suggest that DIAPH3
deletions are enriched by selective pressure. In support of this
hypothesis, Oncomine expression proﬁles indicated DIAPH3
mRNA levels were lower in high stageprostate cancer (PCa) and
inhepatocellular andinvasive breast carcinomas than innormal
tissue [Fig 1B–D; (Finak et al, 2008; Li et al, 2006; Mas et al,
2009)].
Given the prevalence of DIAPH3 lesions in multiple tumour
types, we examined DIAPH3 status in metastases, usingPCa asa
representative disease model. Metastatic PCa lesions can
originate from a single cell (Liu et al, 2009) and may lie
dormant for many years (Wikman et al, 2008). For these
reasons, we characterized the DIAPH3 status of disseminated
tumour cells (DTCs) isolated from bone marrow of PCa patients
(Holcomb et al, 2008). Deletions were more frequent in DTCs
witheitherprostate-conﬁned(31%)ormetastatic(46%)disease
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Figure 1. Genomic loss at DIAPH3 in invasive and metastatic tumours.
A. The DIAPH3 locus on chromosome 13q21.2 is located in a focal peak region of significant deletion (q 0.25) common in prostate, hepatocellular and breast
carcinomas. Only three genes, PCDH17, TDRD3 and DIAPH3, are focally deleted in all cancer subtypes.
B-D. DIAPH3 mRNA levels in prostate (PCa, stage T2/T3), hepatocellular and invasive breast carcinomas compared to normal tissue.
E. Frequency of loss at DIAPH3 (grey line) in DTCs aspirated from bone marrow of patients with prostate-confined cancer (n¼48, blue) and advanced PCa
(n¼11, red). Determined by array CGH and compared to copy number status in the primary tumours (n¼9, green). The chromosome band for each genomic
position is shown; tick marks above indicate gene locations on chromosome 13.
F. DIAPH3 copy number status grouped by Gleason score and compared with metastases.
G. DIAPH3 copy number analysis in matched primary tumours and metastases (Met) reveals significant loss in metastatic disease.
H. DIAPH3 gene copy number in PCa samples grouped by Gleason Score in comparison to metastases (Met).
"
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loss is related to dissemination from the primary site.
To examine this possibility, we evaluated DIAPH3 copy
number in primary tumours and metastases of 148 prostate
cancersby Affymetrix Genome-WideHuman SNP Array6.0 (Liu
et al, 2009). Loss at DIAPH3 was increasingly prevalent with
progression, occurring in 25% of low grade (Gleason score  6),
33% of intermediate grade (Gleason score 7), 40% of high grade
(Gleason score  8), and 61% of metastatic tumours (Fig 1F,
Supporting Information Fig S1B). Oncomine copy number data
conﬁrmed DIAPH3 genomic loss and its signiﬁcant correlation
withdisease progression, which increased from primary tumour
to metastatic lesions and with increasing Gleason score [Fig 1G
and H; (Taylor et al, 2010)].
DIAPH3 knockdown induces an amoeboid phenotype in
transformed cells
In order to examine the biological consequences of DIAPH3 loss,
we employed RNAi against DIAPH3 with multiple independent
shRNAs or siRNAs (Supporting Information Fig S2A, Fig 6C),
which efﬁciently reduced DIAPH3 protein levels but did not
affect the related proteins DIAPH1 and DIAPH2 (Supporting
Information Fig S2B). Because DIAPH3 loss was observed in
breastcancers(Fig1AandD),weemployedthedisease-relevant
human mammary epithelial cell (HMEC) model. While stable
DIAPH3 knockdown did not alter HMEC cell morphology
in 2D culture, it modestly enhanced proliferation (Fig 2A,
Supporting Information Fig S2C and D). In reconstituted
basement membrane gels (3D culture), DIAPH3 silencing
induced enlarged acinar structures with aberrant architecture
and distribution of Laminin V (Fig 2A, Supporting Information
Fig S3A and B), resembling that seen with ErbB2 activation
(Debnath et al, 2002). These results suggest that in normal
epithelia, DIAPH3 may act to suppress oncogenic behaviour.
Next, we investigated the consequences of DIAPH3 lossin the
context of HRAS-induced cellular transformation. We generated
stable populations of HRAS
V12-transformed HMECs in which
DIAPH3 was silenced (Supporting Information Fig S3C). In 2D
culture, HMEC-HRAS
V12 cells appeared spindle-shaped, con-
sistent with EMT (Fig 2B, top). In contrast, DIAPH3-depleted
HMEC-HRAS
V12 cells were refractile, with rounded morpholo-
gies (Fig 2B). Time-lapse video microscopy demonstrated that
these cells displayed abundant, reversible eruption of blebs,
reduced cell–cell contact, and increased rates of random
motility, in comparison to HMEC-HRAS
V12 cells (Fig 2C
and D, Supporting Information Movies S1, S2). These features
are indicative of amoeboid behaviour (Wolf et al, 2003).
In 3D culture, HMEC-HRAS
V12 produced large cell aggregates
(acini)withpenetrationofthematrixbycordsofspindle-shaped
cells (Fig 2B, top inset, Supporting Information Fig S3D). In
contrast, DIAPH3-deﬁcient HRAS
V12 cells produced acini that
progressively and dramatically lost structural integrity, coin-
ciding with extensive migration of round cells into the matrix
(Fig 2B, lower insets, Supporting Information Fig S3D).
Signiﬁcantly, while HRAS
V12-HMEC cells were poorly invasive
through collagen I, DIAPH3 knockdown in this cell background
promoted invasion (Fig 2E). These ﬁndings indicate that, when
combined with activated HRAS, DIAPH3 down-regulation
promotes an amoeboid phenotype and increases invasion.
To determine whether this amoeboid transition can be
similarly induced in genuine cancer cells, we silenced DIAPH3
in DU145 PCa cells. As in the genetically deﬁned HRAS
V12-
HMEC model, DIAPH3 knockdown in DU145 cells induced a
rounded morphology and formation of membrane blebs when
cells were embedded in collagen (Fig 2F). In line with this
promotion of amoeboid behaviour (Fig 2G), DIAPH3 knock-
down enhanced the invasiveness of DU145 cells (Fig 2H,
Supporting Information Fig S3E). DIAPH3-deﬁcient cells were
hypersensitive to chemo-attractants, including EGF.
Amoeboid cells display weakened substrate adhesions,
allowing high cell velocities (Schmidt & Friedl, 2010). This fast
‘gliding’ mode can be driven by Rho-kinase (ROCK)-dependent
force generation through myosin light chain (MLC2) phosphor-
ylation, and is distinct from integrin-mediated traction force
generation characteristic of mesenchymal motility (Friedl &
Wolf, 2010). DIAPH3 silencing promoted focal adhesion
disassembly, as evidenced by an altered pattern of focal
adhesion kinase (FAK) phosphorylation [Fig 3A, 3B (Hamadi
et al, 2005)], and also evoked high levels of phosphorylated
MYPT1, a ROCK substrate (Fig 3C and D), and MLC2 (Fig 3E). In
DIAPH3-deﬁcient cells, both activated and total MLC2 were
enriched at the cell cortex (Fig 3F, Supporting Information
Fig S4A–C), where cortical MLC2 colocalized with phalloidin. In
unsilenced cells, cortical MLC2 was less pronounced and
co-localizedinsteadwithphalloidininstressﬁbres.Theseﬁndings
are consistent with the ROCK-mediated cortical localization of
MLC2reportedtobedisplayedbyamoeboidcells(Pinner&Sahai,
2008; Sahai & Marshall, 2003; Wyckoff et al, 2006).
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Figure 2. DIAPH3 knockdown induces an amoeboid phenotype in transformed cells.
A. Morphology of DIAPH3-depleted HMEC, compared to control cells. Plastic (2D), basement membrane cultures (3D). Scale¼200mm.
B. HRAS
V12cellsgrown in 2Dadopt around, refractileappearance whenDIAPH3 is silenced. Scale¼100mm.HMEC-HRAS
V12cells formcell aggregates withcord-
like protrusions in 3D. DIAPH3 depletion causes junctional instability, with migration of single cells into the surrounding matrix (inset, right). Scale¼200mm.
C. Representative trajectories of control (green) and DIAPH3-deficient (red) HMEC-HRAS
V12 cells.
D. Quantification of migration speed, determined from C.
E. DIAPH3-silenced HRAS
V12-HMEC display increased invasiveness.
F. Growth of DIAPH3-deficient and control DU145 cells on a thick layer of collagen I. Arrowheads mark cell surface blebbing (top). Visualization of the
cytoskeleton with phalloidin by immunofluorescence (IF) shows prominent cortical actin in DIAPH3-deficient cells (arrowhead, bottom). Scale¼50mm.
G. Increase in amoeboid morphology following expression of DIAPH3 siRNA.
H. Invasion of collagen I by DU145 cells, with FBS or EGF as chemo-attractants, is increased in DIAPH3-deficient cells (N 2 independent trials). See also
Supporting Information Movies S1 and S2.
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We next sought to examine the mechanisms underlying
induction of the amoeboid transition by DIAPH3 knockdown.
Forminslocalizetoendosomesandregulatevesiculartrafﬁcking
(Fernandez-Borja et al, 2005; Gasman et al, 2003; Wallar et al,
2007). Because endocytosis governs the spatiotemporal regula-
tion of receptor tyrosine kinases (RTKs), and chemotactic
sensitivity to EGF was enhanced in DIAPH3-silenced cells
(Fig 2H), we hypothesized that DIAPH3 may regulate turnover
and trafﬁcking of EGFR. Enforced expression of DIAPH3
markedlyacceleratedthekineticsofEGFRturnoverandreceptor
inactivation in response to EGF and under steady-state
conditions (Fig 4A, 4B). Further supporting a functional
relationship, DIAPH3 and EGFR co-localized in endosomes
(unpublished observations). Thus, we examined the inﬂuence
of DIAPH3 on endocytic trafﬁcking of EGFR. In the absence of
EGF and the presence of endogenous DIAPH3, EGFR co-
localized at the plasma membrane with the recycling marker
Rab11 (Fig 4C). In response to ligand, EGFR translocated to a
peri-nuclear region and co-localized with the early endosome
marker Rab5 (Fig 4D). In contrast, DIAPH3 silencing promoted
association of EGFR with endosomes enriched in Rab11, Rab5
Research Article
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suggest that loss of DIAPH3 disrupts vesicular transport, leading
to EGFR accumulation in endosomes.
To investigate how DIAPH3 affects endosomal trafﬁcking
of EGFR, we assessed its inﬂuence on the actin and micro-
tubule (MT) cytoskeletons, which govern short- and long-range
vesicular transport, respectively (Soldati & Schliwa, 2006). While
rearrangement of the actin cytoskeleton was associated with
DIAPH3 silencing (Fig 3F, Supporting Information Fig S4C), no
conspicuous actin defects were detected. Combined with the
observation that endosomes did not accumulate at the cell cortex
but were dispersed throughout the cytoplasm in DIAPH3-
deﬁcient cells (Fig 4C–E), these data suggest that DIAPH3 loss
does not signiﬁcantly inﬂuence short-range EGFR trafﬁcking.
In addition to regulating actin dynamics, formins also
promote MT stability (Bartolini et al, 2008). Enforced DIAPH3
markedly increased tubulin acetylation (Fig 5A, Supporting
Information Fig S5A), an indication of MT stabilization (Verhey
& Gaertig, 2007). Conversely, DIAPH3 silencing decreased
tubulin acetylation and was associated with MT fragmentation
(Fig 5B–G, Supporting Information Fig S5B). Notably, treatment
of cells with the MT depolymerizing agent nocodazole
phenocopied the accumulation of EGFR in internal vesicles
and some amoeboid features (Supporting Information Fig S5C
and D) induced by DIAPH3 knockdown.
These ﬁndings imply that DIAPH3 deﬁciency disrupts MT
stability and endosome processing, thereby sequestering and
preserving EGFR in early endosomes. Disrupted trafﬁcking
coincided with EGFR hyper-activation, as evidenced by
increased auto-phosphorylation of activating residues and
decreased phosphorylation of the inhibitory Thr669 site
(Fig 6A). EGFR activation was enhanced in DIAPH3-silenced
cells in response to EGF (Supporting Information Fig S6A).
DIAPH3 deﬁciency also increased phosphorylation of the EGFR
effectors MEK and ERK (Fig 6A and B, Supporting Information
Fig S6A), which inversely and dose-dependently correlated with
DIAPH3 levels (Fig 6C, Supporting Information Fig S6B). Even
under serum-free conditions, DIAPH3 depletion increased ERK
phosphorylation sixfold (Fig 6D), and potentiated the response
to EGF (Fig 6E, Supporting Information Fig S6C), with a twofold
to fourfold increase in phosphorylated ERK at each time point
post-stimulation. This ligand-independent hyperactivation of
EGFR and MEK/ERK is consistent with reports linking early
endosome-localized EGFR to sustained activation of the RAF/
MEK/ERK pathway (Sorkin & von Zastrow, 2009). Collectively,
these ﬁndings support an important role for DIAPH3 in
regulation of EGFR trafﬁcking and signalling.
Sensitivity of DIAPH3-deficient cells to anti-neoplastic agents
Because DIAPH3 silencing induces amoeboid behaviour and
strongly activates ERK, we tested the relevance of MEK/ERK
signalling in this scenario. Treatment of DIAPH3-deﬁcient
DU145, HMEC-HRAS
V12 and A375P melanoma cells with the
MEK1/2 inhibitor PD98059 converted cells to a more mesench-
ymal morphology (Fig 7A, Supporting Information Fig S7A).
Pharmacologic reversion of amoeboid features could be
reversed by drug washout (unpublished observations). A375P
has been used as a model to study amoeboid properties (Sanz-
Moreno et al, 2008). Collectively, these data indicate that MEK/
ERK pathway activation can contribute to amoeboid behaviour
in diverse cell backgrounds.
EGFR is a frequent target for therapeutic intervention.
However, responsiveness to tyrosine kinase inhibitors (TKI, e.g.
geﬁtinib)maybedictatedbythereceptor’ssubcellularlocalization
(Huang et al, 2009). Because DIAPH3 knockdown modulates
EGFR localization and activity, we asked whether DIAPH3
deﬁciency affects TKI sensitivity. In control DU145 cells, EGF
stimulation induced amoeboid features (blebbing), which was
suppressed by geﬁtinib (Fig 7B and C, Supporting Information
Movie S3). In contrast, the amoeboid phenotype was constitutive
and ligand-independent in DIAPH3-silenced cells. Notably, these
cells were unresponsive to the TKI. These ﬁndings suggest that
DIAPH3 loss alters sensitivity to EGFR inhibitors.
Taxanes such as paclitaxel and docetaxel are ﬁrst-line
chemotherapies for metastatic breast and prostate cancers,
which we show are prone to DIAPH3 loss (Fig 1). However,
development of resistance limits their efﬁcacy in patients.
Taxanes stabilize MTs, suggesting their potential to down-
regulate EGFRsimilarly toDIAPH3. Weobserved, however, that
EGFR activation persisted in the presence of docetaxel
(Supporting Information Fig S7B) and paclitaxel (unpublished
observations), in line with reports that these agents disrupt
endosomal EGFR trafﬁcking (Sonee et al, 1998).
DIAPH3 suppresses the amoeboid phenotype
Induction of the amoeboid phenotype by DIAPH3 knockdown
suggests that enforced DIAPH3 expression may counteract this
transition. We stably expressed GFP-DIAPH3 in PC3 PCa cells
and in U87 glioblastoma cells.Of note, U87 expressed the lowest
levels of DIAPH3 among the cell lines we tested. U87 and PC3
Research Article
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Figure 4. DIAPH3 regulates endocytic trafficking of EGFR.
A. Enforced DIAPH3 accelerates EGFR turnover. COS7 cells expressing empty vector (Vo) or DIAPH3 were serum-depleted overnight, treated with EGF for the
indicated times, and lysates blotted with the antibodies shown.
B. GFP-DIAPH3-positiveCOS7cellsshowstronglyreducedEGFRlevels(lowerpanel,arrowhead)incomparisonwithGFP-transfectedcontrolcells(upperpanel)or
adjacent untransfected cells. Scale¼20mm.
C. Left, Co-localization of Cy3-labeled EGFR with FITC-labelled Rab11 in DU145 cells expressing DIAPH3 siRNAs. Right, Cell peripheries are shown in grey, and
areas of co-localization in black. Insets show predominance of EGFR at the plasma membrane (top) or in endosomes (bottom). Scale¼20mm.
D. Left, Co-localization of Cy3-labeled EGFR with FITC-labelled Rab5 upon ligand binding (þEGF). DIAPH3 loss evokes an increase in EGFR internalization in the
absence of ligand ( EGF), as shown by accumulation in endosomes (insets and arrowheads) and co-localization with Rab5. Scale¼20mm. Right, Quantitation
of EGFR-enriched endosomes.
E. Cy3-labeled EGFR, which is localized at the plasma membrane in DU145 cells expressing control siRNA, is internalized and co-localizes with the FITC-labelled
early endosome marker EEA1 in DU145 cells expressing DIAPH3 siRNAs. Scale¼10mm( N 2 independent trials).
"
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Figure 5. DIAPH3 regulates microtubule topology and stability.
A. Increased acetylated tubulin (Ac-tubulin) in PC3 cells stably expressing DIAPH3.
B. Reduced Ac-tubulin levels in DU145 cells silenced for DIAPH3.
C. Left, Ac-tubulin IF showing MT fragmentation in DIAPH3-deficient DU145 cells grown in 3D. Right, MT topology was rendered by ImageJ. Insets, cells stained
with cholera toxin B (CTxB, green). Scale¼10mm.
D. Pixel intensity of C was quantified as a 2D contour plot, as a function of intensity in the x versus y planes (illustrated schematically, top).
E. The pixel intensity of Ac-tubulin was quantified in silenced or unsilenced DU145 cells. Cell peripheries were outlined as in C, tubulin intensity integrated
withintheenclosedarea,andaverageintensitiesineachconditiondetermined. Averageintensityvaluesdeterminedfromthreeindependenttrials (Student’s
t-test, p¼0.0033). N¼total cell number.
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blebs and rounded morphologies (Fig 8A and B, Supporting
Information Fig S8A). Enforced DIAPH3 altered the phenotype
of both cell lines, suppressing amoeboid blebbing and inducing
formation of prominent lamellipodia, a typical mesenchymal
feature (Fig 8A, B and F, Supporting Information Fig S8A).
DIAPH3 also increased levels of the mesenchymal marker
N-cadherin (Fig 8C), in concert with increased stress ﬁber
formation (Fig 8E, Supporting Information Fig S8B), suggesting
that DIAPH3 promotes an amoeboid to mesenchymal transition.
The data shown above position DIAPH3 within the EGFR
pathway. Consistent with this, we identiﬁed an EGF-sensitive
phospho-serine at position 624 in the DIAPH3 primary sequence
by tandem mass spectrometry (Supporting Information Fig
S9A). S624 is located within the last of ﬁve polyproline/SRC
homology three binding motifs in the FH1 domain (Fig 8D). This
site was validated by stable isotope labelling (Supporting
Information Fig S9B and C) and conﬁrmed to be EGF-responsive
using a custom phosphosite-speciﬁc antibody (Supporting
Information Fig S9D and E). DIAPH3 function was modulated
by its phosphorylation status at S624. A phospho-null mutant at
this site (S624A) promoted stress ﬁbre formation, a mesench-
ymal characteristic (Fig 8E), and suppressed amoeboid blebbing
(Fig 8F) to a greater degree than the unmodiﬁed protein, while a
phospho-mimetic mutant (S624E) was impaired in both
activities (Fig 8E and F). These ﬁndings support the conclusion
that DIAPH3 suppresses amoeboid blebbing and is functionally
inhibited by phosphorylation at S624, which occurs in response
to EGF treatment (Supporting Information Fig S9E).
DIAPH3 loss promotes metastasis and is associated with
metastatic human prostate cancer
Our ﬁndings thus far suggest that DIAPH3 loss promotes motility,
invasion,andincreasedoncogenicsignalling,all pre-requisitesfor
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Figure 6. DIAPH3 knockdown enhances EGFR
signalling.
A. EGFR is active in DIAPH3-silenced COS7 cells, as
shown by increased tyrosine phosphorylation at
activating sites and decreased phosphorylation of
the T669 inhibitory site.
B. Enhanced pMEK1/2 in DIAPH3-depleted DU145
cells.
C. Targeting of DIAPH3 with four independent siR-
NAs in COS7 leads to >90% depletion, which
inversely correlates with pERK1/2 levels.
D. DIAPH3 depletion in serum-depleted cells
enhances pERK1/2 levels.
E. Acute, sustained phosphorylation of ERK1/2 in
response to EGF in DIAPH3-depleted versus
control cells (two-way ANOVA, p¼0.0068; N 2
independent trials).
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metastasesinnudemice,inducedbytailveininjectionofDIAPH3-
silenced DU145 cells, were enhanced relative to unsilenced cells
(Fig 9A and B). Both the number and size of metastatic foci were
potentiated by DIAPH3 knockdown (Fig 9B and data not shown).
Additionally,largetumourthromboticemboliwereobservedonly
in lung sections from mice that underwent injection of DIAPH3-
silenced cells (Fig 9C). Detection of human cytokeratin 18 (CK18)
in the lung metastases demonstrated the lesions’ human origin
(Fig 9D). This was further conﬁrmed by puromycin resistance of
cells from dissociated lesions in cell culture. Together, these
ﬁndings indicate that DIAPH3 silencing enhances experimental
metastasis in mice.
Lastly, we examined expression of the DIAPH3 protein with
PCa progression using a cohort of 90 human prostate specimens
in a tissue microarray format and a validated anti-DIAPH3
antibody (Supporting Information Fig S2B). While DIAPH3
protein levels did not demonstrably change between benign and
organ-conﬁned carcinoma, we observed a dramatic reduction of
DIAPH3 protein levels in metastatic lesions in comparison
with normal tissue (p¼0.018) and organ-conﬁned tumours
(p¼0.007, Fig 9E and F). These results are in agreement with
our genomic analyses (Fig 1E–H) and indicate that loss of the
DIAPH3 locus functionally results in signiﬁcant loss of the
protein in human metastatic disease.
DISCUSSION
This study provides evidence that the formin DIAPH3 belongs
to a novel class of metastasis suppressors that inhibits
conversion to an amoeboid phenotype. Inactivation of
this gene appears relevant to several human malignancies,
including prostate and breast carcinomas. We identiﬁed a
consensus area of signiﬁcant recurrent deletion on chromosome
13 encompassing the DIAPH3 locus and showed that DIAPH3
genomic loss and/or decreased DIAPH3 expression occurs
in organ-conﬁned tumours, but occurs at higher frequency
in advanced disease, circulating prostate tumour cells, and
metastatic lesions. We show that DIAPH3 silencing enhances
tumour cell invasion, promotes amoeboid features in disparate
cell backgrounds, and enhances experimental metastasis
in vivo.
This is the ﬁrst example of a genomic lesion affecting a direct
cytoskeletal regulator that governs the amoeboid transition.
Because amoeboid behaviour enables cells to squeeze through
gaps in the ﬁbrillar matrix, amoeboid cells are proposed to
possess a higher proclivity to disseminate and metastasize
(Sanz-Moreno & Marshall, 2010). We provide evidence that
DIAPH3 deﬁciency promotes a wide range of amoeboid
characteristics, and can cooperate with a canonical activated
oncogene. In a mammary epithelial background, activated
Research Article
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Figure 7. Sensitivity of amoeboid features to MEK1/2 and EGFR inhibition.
A. Amoeboid features induced by DIAPH3 silencing in human HMEC-HRAS
V12, A375P melanoma and DU145 cells can be reverted by PD98059 (50mM). N 2
independent trials.
B,C. Amoeboid blebbing induced by EGF (10nM) in control cells is sensitive to the EGFR inhibitor Gefitinib (2mM), while induction by DIAPH3 silencing is less
sensitive to both treatments, (C) Representative micrographs, (B) See also Supporting Information Movie S3.
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context of activated HRAS resulted in an amoeboid transition
consisting of a dramatic morphologic transformation in base-
ment membrane cultures and high invasive potential (Fig 2).
These ﬁndings suggest that the oncogenic background of tissues
in which DIAPH3 is lost makes an essential contribution to
tumour behaviour.
We also showed that an endosomal trafﬁcking defect can
elicit amoeboid behaviour. We propose a model (Fig 10)
whereby DIAPH3 loss causes cytoskeletal disruption, inhibits
endocytic down-regulation of RTKs, and leads to persistent
activation of downstream effectors. That DIAPH3 down-
regulation enhances endosomal accumulation of EGFR is
notable given recent reports implicating endocytic trafﬁcking
Research Article
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ing increased signalling from EGFR, VEGFR and c-MET if
endosome processing is compromised (Joffre et al, 2011;
Lanahan et al, 2010; Wang et al, 2009). Our ﬁndings suggest
that amoeboid behaviour is a disease-relevant outcome of the
ability of DIAPH3-silenced tumour cells to usurp the endocytic
machinery.
Our model proposes that deregulated endosomal trafﬁcking
and signalling defects associated with DIAPH3 silencing arise
from MT disruption. DIAPH3 loss induced MT instability and
Research Article
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correlation between tubulin acetylation and EGFR degradation
(Deribe et al, 2009; Gao et al, 2010). MT instability is emerging
as a contributor to the amoeboid phenotype (Belletti et al, 2008;
Berton et al, 2009). Our ﬁndings suggest that DIAPH3 is a key
regulatory node in the transition between amoeboid and
mesenchymal tumour cell phenotypes and that MT disruption
may affect amoeboid and mesenchymal features at multiple
levels.
The sustained endosomal localization of EGFR consequent to
DIAPH3 downregulation may be clinically relevant. Response of
a tumour cell population to a TKI can be inﬂuenced by
distribution of intracellular EGFR, such that some ‘sensitive’
cells display EGFR on the plasma membrane while ‘resistant’
cells exhibit perinuclear localization (Huang et al, 2009).
Alternatively, while the ligand-bound receptor undergoes
normal endocytic trafﬁcking in ‘responsive’ cells, transport to
lysosomes can be defective in ‘resistant’ cells (Nishimura et al,
2007). We observed similar responses with DIAPH3 deﬁciency,
which markedly reduced sensitivity to a TKI. Our ﬁndings are
suggestive that DIAPH3 loss can induce resistance to EGFR
inhibitors. This possibility deserves further exploration.
The RAS/MAPK axis is upregulated in 90% of metastatic PCa
lesions (Taylor et al, 2010), and hyper-activation of ERK is
implicated in PCa progression (Gioeli et al, 1999). However, it
remains unclear how this pathway is activated, since compre-
hensive proﬁling of prostate tumours did not reveal activating
mutations in BRAF or HRAS (Burger et al, 2006; Thomas et al,
2007). It is notable, then, that in PCa cells DIAPH3 deﬁciency
upregulates ERK activity. Our results raise the interesting
possibility that MEK inhibitors may be useful to target advanced
disease in patients with tumours with DIAPH3 loss.
Two recent reports assessed DIAPH3 in the context of cell
invasion. Lizarraga et al. demonstrated that DIAPH3 silencing
inhibits formation of ﬁlopodia-like invadopodia, invasion and
degradation of 3D-matrices (Lizarraga et al, 2009). We observed
DIAPH3 loss to induce a switch to an amoeboid phenotype, in
which dependence on proteases for invasion is reportedly
reduced (Friedl & Wolf, 2010). However, while DIAPH3
silencing suppressed invasion of MDA-MB-231 cells through
Research Article
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amoeboid transition.
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to promote invasion through collagen I. Using an siRNA screen
for formin family regulators of membrane blebbing, Stastna
et al. reported that DIAPH3 silencing inhibited bleb formation
and promoted cell spreading in HeLa cells (Stastna et al, 2011).
Of the multiple transcripts of the DIAPH3 locus, Isoform 1
mediatedblebformation,while anactivatedvariantofIsoform7
instead promoted ﬁlopodia. Consistent with the last observa-
tion, we observed a signiﬁcant reduction in ﬁlopodia following
DIAPH3 silencing of HMEC-HRAS
V12 (unpublished observa-
tions).WeemployedIsoform7forourstudies,howeverDIAPH3
silencing potentiated bleb formation, reduced adhesion and
increased rates of migration in COS7, DU145 and HMEC.
Although genetic heterogeneity or different characteristics of
diverse ECM used in these in vitro studies may play a role in
these diverse effects, collectively they are consistent with the
conclusion that DIAPH3 resides at an important signaling node
that controls invasive behaviour. Importantly, the genomic loss
data and other ﬁndings from human cohorts that we present
here are consistent with the conclusion that DIAPH3 inactiva-
tion is likely to promote aggressive behaviour in prostate, breast
and possibly other tumour types. In the present study, we also
identiﬁed a serine residue in the DIAPH3 FH1 domain
that seems to result in inactivation of the protein when
phosphorylated. This ﬁnding suggests that DIAPH3 might be
inactivated by upstream signaling pathways in addition to gene
disruption.
Reports have speculated about the presence of a tumour
suppressor at 13q21 that is independent of RB1. A recent study
evaluated somatic homozygous deletions (HDs) at high
resolution in 746 cancer cell lines (Bignell et al, 2010),
identifying an ‘unexplained’ HD cluster on chromosome 13
that exhibits a signature similar to known tumour suppressors.
This cluster was separate from the dominating HD cluster
affecting the RB1 locus and had not been assigned to a known
tumour suppressor gene. DIAPH3 is a candidate non-canonical
tumour suppressor in this region.
In conclusion, identiﬁcation of DIAPH3 as a protein capable
of mediating the switch between mesenchymal and amoeboid
phenotypes provides new insight into the molecular processes
of metastasis, and may facilitate design of more effective
strategies against advanced disease.
MATERIALS AND METHODS
Copy number analysis
DNA copy number alterations were analysed with the Integrated
Genomics Viewer using genome-wide GISTIC data (Beroukhim et al,
2007). DIAPH3 copy number status of PCa patients was analysed using
comparative genomic hybridization (cCGH) and Affymetrix Genome-
Wide SNP Array data (Liu et al, 2009).The frequency of DIAPH3 loss in
circulating tumours cells was assessed using array CGH data (Holcomb
et al, 2008).
Immunohistochemistry and tissue microarrays
The human prostate tissue microarray consisted of normal/benign
(n¼16), prostate tumour (n¼22) and metastatic tissue cores
(n¼24). Immunohistochemistry was performed with DIAPH3
(HNH3.1) or cytokeratin 18 antibodies.
Immunoblotting was performed as described in Supporting Informa-
tion.
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The paper explained
PROBLEM:
While metastatic disease underlies most cancer-related
mortality, few genetic lesions that select for metastatic tumour
cell variants have been identified. Amoeboid motility is one of
several diverse modes adopted by disseminating tumour cells.
Elucidation of networks and critical signaling nodes that confer
or restrain the amoeboid phenotype would facilitate discovery of
novel therapies to control metastasis. The DIAPH3 locus,
encoding the protein Diaphanous-related formin-3 (DIAPH3),
resides at a chromosomal location that is frequently lost in
metastatic prostate cancer. The potential functional significance
of loss of this locus is unknown.
RESULTS:
Analysis of genome-wide, SCNA revealed that the DIAPH3 locus
was a consensus area of chromosomal deletion common to
several carcinomas. DIAPH3 deletions accumulated during
disease progression, were strongly associated with metastatic
disease, and were prevalent in DTCs from patient bone marrow
aspirates. DIAPH3 silencing cooperated with oncogenic trans-
formation to evoke an amoeboid phenotype in several tumour
cell backgrounds. Loss of DIAPH3 caused cytoskeletal and
endocytic trafficking defects through which EGFR/MEK/ERK
signaling was hyperactivated. Pharmacologic inhibition of MEK
suppressed the amoeboid phenotype, but tyrosine kinase
inhibitors were ineffective. DIAPH3 silencing potentiated for-
mation of pulmonary metastases in vivo, and its loss correlated
with metastasis in human tumours.
IMPACT:
This is the first report showing that loss of a cytoskeleton
remodelling protein, encoded by a locus that is lost at high
frequency in multiple tumours and is strongly associated with
metastasis, results in acquisition of the amoeboid cancer cell
phenotype. These results may have prognostic utility to
distinguish low-risk from high-risk disease.
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For sequences and transfection methods, see Supporting Information.
Multiple, independent hairpins and duplexes (>4) produced similar
results in numerous readouts.
Immunofluorescence
Antibodies used: Acetylated tubulin and Rab11 (Abcam), FITC-
conjugated anti-FLAG (Sigma), FITC-conjugated anti-EEA1 (BD Bios-
ciences), EGFR (Biosource), FITC-Cholera Toxin B (CTxB, Sigma),
FAK(Y397), MLC2, pMLC2(S19) and Rab5, (Cell Signaling). F-actin
was detected with rhodamine-phalloidin (Invitrogen). An Axioplan 2
microscope (Zeiss) equipped with an AxioCam camera was used for
fluorescence imaging.
Quantitation of EGFR-positive endosomes and focal adhesions:
Duplicate slides were evaluated by three observers blinded to the
experimental group in two independent experiments, in >50 cells/
condition per experiment.
Tubulin acetylation: DU145 cells were incubated with acetylated
tubulin antibodies, and fluorescence quantified using Axiovision 4.5
software (Zeiss). Images were rendered using ImageJ processing
software. Where noted, cells were stained with rhodamine–phalloidin
or FITC-CTxB prior to fixation.
Rab11 co-localization: DU145 cells were incubated with antibodies
against Rab11 and EGFR, and fluorescent co-localization analysed
with ImageJ. Regions with pixel intensity common to Rab11 and EGFR
were highlighted.
Where indicated, cells plated on collagen I were pretreated with
nocodazole (2mM, Sigma) for 30min, and processed as above with
EGFR antibodies.
Morphogenesis assay
Three-dimensional culture of epithelial cells was performed as
described (Debnath et al, 2002). Briefly, cells were seeded onto
Matrigel basement membrane matrix, and acini size measured and
analysed with Fiji image processing software.
Luminescence proliferation assay
Viable cells were quantified with the CellTiter-Glo assay (Promega),
with luminescence measured every 24h with a FLUOstar Omega
platereader (BMG Labtech).
Experimental Metastasis Model
Animal studies were conducted in compliance with Children’s Hospital
Boston IACUC guidelines using BALB/c nude mice (Massachusetts
General Hospital). DU145 cells expressing control or DIAPH3 shRNAs
were resuspended in HBSS, injected into the tail veins of anesthetized
mice (15 animals per group), and after 8 weeks mice were sacrificed,
lungs isolated and each lobe fixed individually in 10% formalin.
Time-lapse video microscopy and track-plot analysis
Cell migration was monitored with an inverted microscope, collecting
images every 2min for 30h, and movies analysed using Bioimaging
software (Andor).
Real-time invasion assay
Cells labelled with CellTracker Red CMTPX (Molecular Probes) were
seeded onto collagen I-coated FluoroBlok
TM inserts, and fluorescence
intensity of cells migrated towards chemo-attractants monitored at 6
or 12h.
Statistical analyses
Student’s t-test (two-tailed) was used if data were normally
distributed. Otherwise, Mann–Whitney U, ANOVA, or Fisher’s exact
tests were used. Analyses were performed with Prism 5.0a software.
Data were plotted as mean SD.
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